Northwest Biotherapeutics, Inc. (OTCPK: NWBO)
Health Care · Biotechnology · US
$0.17
-11.67% today · -31.2% 1Y
Northwest Biotherapeutics, Inc. (OTCPK: NWBO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $286.30M and employs 105 people.
Over the last twelve months the share price has lost 31.2%, trading between 0.14 and 0.37.
Tweenvest scores Northwest Biotherapeutics, Inc. across four factors: quality 4/100, value 68/100, growth 0/100. Its strongest factor is value.
NWBO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $286.30M
- Revenue (TTM)
- $2.17M
- P/E
- —
- EPS
- -0.03
- Dividend yield
- —
- Beta (5Y)
- -0.62
- 52-week high
- $0.37
- 52-week low
- $0.14
- Avg volume (3M)
- —
- Shares outstanding
- 1.69B
- Employees
- 105
- Next earnings
- —
About Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology firm that creates personalized immune-based treatments for various cancers, operating both within the United States and internationally. Their product pipeline relies on DCVax, a proprietary technology platform. This platform harnesses a patient's own activated dendritic cells to stimulate their immune system to combat cancerous cells. The company's leading therapeutic candidate, DCVax-L, has successfully completed Phase III clinical trials targeting Glioblastoma multiforme, an aggressive form of brain cancer. Additionally, Northwest Biotherapeutics is progressing DCVax-Direct through Phase I/II clinical studies, focusing on the treatment of inoperable solid tumors. Founded in 1996, the company's headquarters are situated in Bethesda, Maryland.
- ISIN
- US66737P6007
- Founded
- 1996
- Listed since
- Dec 14, 2001
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.72 | -0.09% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $443.99 | +1.06% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.30 | +0.12% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $547.86 | -0.03% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $828.88 | -0.62% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $139.68 | -3.72% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.